TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03562195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 milligrams
Description: Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as 0.9 percent sodium chloride solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
Study: NCT03304678

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus 2mg
Description: Patients with LAM, whose treating physicians have decided that they need to start treatment with sirolimus will be referred to the NIH Clinical Center for these studies.
Study: NCT06424236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Open-label administered Subcutaneously every 4 weeks at escalating doses
Study: NCT03158844

Intervention type: OTHER
Intervention: Standard of care
Description: Routine standard of care per Ministry of Health protocol, including blood draws and examinations.

Intervention type: OTHER
Intervention: Standard of care
Description: Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
Study: NCT04231773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 40 parts per million dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 40 parts per million dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
Study: NCT04289181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals
Description: 4 weeks of medically tailored meals
Study: NCT04366414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hook breathing removing nose-clip
Description: Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual breathing (UB)
Description: Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
Study: NCT03118986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
Study: NCT02407301

Intervention type: OTHER
Intervention: cough airflow measure
Description: Participants will produce multiple voluntary coughs for cough airflow assessment.

Intervention type: OTHER
Intervention: vocal tasks
Description: The assessment of glottal closure will be performed during phonation tasks.

Intervention type: OTHER
Intervention: true vocal fold movement
Description: The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.

Intervention type: OTHER
Intervention: spirometry test
Description: The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.

Intervention type: OTHER
Intervention: maximum expiratory pressure (MEP)
Description: The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
Study: NCT03562143

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
Study: NCT04414241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
Study: NCT00989911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
Study: NCT03813355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: transcranial Direct Current Stimulation (tDCS) during 20 sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: transcranial Direct Current Stimulation (tDCS) during 20 sessions
Study: NCT00671658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: 300 mg/m2 by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein or by mouth (P.O.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 ug/kg subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m2 a day by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated asparaginase
Description: 2000 International units/m2 by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg (flat dose) within 72 hrs after completion of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: 40 mg by vein for Courses 2,4,6,8
Study: NCT00242931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative stem cell conditioning regimen
Description: Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181.
Study: NCT04053335

Intervention type: BEHAVIORAL
Intervention: Multicomponent Physician Performance Peer-Comparison Feedback Intervention
Description: The intervention will consist of 5 components delivered simultaneously~* Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~* Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~* Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~* Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~* Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls
Study: NCT02918370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active comparators in appearance.
Study: NCT00474123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80 mg/day for 6 weeks
Description: Simvastatin 80 mg/day, single dose, for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg / Simvastatin 20 mg
Description: Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
Study: NCT00772538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 5mcg/day
Description: Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo
Study: NCT01903356

Intervention type: DRUG
Intervention: Trajenta duo
Description: Linagliptin and Metformin
Study: NCT03728868

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplementation with placebo once a day for 8 consecutive weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose F. prausnitzii and D. piger
Description: Dietary supplementation with high dose F. prausnitzii and D. piger once a day for 8 consecutive weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose F. prausnitzii and D. piger
Description: Dietary supplementation with low dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
Study: NCT05471765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withdrawal of Continuous Positive Airway Pressure device
Description: After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withdrawal of Continuous Positive Airway Pressure device
Description: After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternation usage of Continuous Positive Airway Pressure Device
Description: After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternation usage of Continuous Positive Airway Pressure Device
Description: After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
Study: NCT02946086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE with prismatic adaptation
Description: Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HABIT-ILE without prismatic adaptation
Description: Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
Study: NCT02574624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular assistance
Description: Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
Study: NCT04514185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive industrial exoskeleton for the upper limb
Description: The goal is to compare the human response to the simulated industrial tasks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The protocol will be performed without exoskeleton
Description: The protocol will be performed without exoskeleton
Study: NCT02669810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROTHERACYTES
Description: ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment for CHF post AMI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment for CHF post AMI
Study: NCT01874236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% bupivacaine
Description: Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: .75% bupivacaine
Description: Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: .75% bupivacaine
Description: Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
Study: NCT00360230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 2 different formulations are tested. For each formulation, 3 different dosing schedules are tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 2 different formulations are tested. For each formulation, 3 different dosing schedules are tested

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 2 different formulations are tested. For each formulation, 3 different dosing schedules are tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 2 different formulations are tested. For each formulation, 3 different dosing schedules are tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 2 different formulations are tested. For each formulation, 3 different dosing schedules are tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 2 different formulations are tested. For each formulation, 3 different dosing schedules are tested

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabipur
Description: 3-dose intramuscular injection.
Study: NCT04351542

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
Study: NCT02640586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: three MR examination
Description: Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
Study: NCT02043756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: 6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: 10mg/m2, IV ,on day 1 of each 28 day,3 cycles
Study: NCT06013735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride solution
Description: sodium fluoride solution mouth rinse (0.2%).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guava leaves aqueous extract
Description: guava leaves aqueous extract mouth rinse (0.5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pomegranate peel aqueous extrac
Description: pomegranate peel aqueous extract mouth rinse (0.5%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: placebo distilled water
Study: NCT02800538

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intragastric infusion of nutrient
Description: Intragastric infusion of nutrient that can be widely found in daily food or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intragastric infusion of nutrient
Description: Intragastric infusion of nutrient that can be widely found in daily food or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intragastric infusion of nutrient
Description: Intragastric infusion of nutrient that can be widely found in daily food or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: intragastric infusion of nutrient
Description: Intragastric infusion of nutrient that can be widely found in daily food or placebo.
Study: NCT03516123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3006
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s).
Study: NCT03562143

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
Study: NCT00345293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell vaccine (DC/PC3)
Description: ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
Study: NCT00439803

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX601
Description: 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of placebo given at T=0, 8, 24 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX601
Description: 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of placebo given at T=0, 8, 24 weeks via the SC route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX601
Description: 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AVX601
Description: 3 doses of placebo given at T=0, 8, 24 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX601
Description: 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of placebo given at T=0, 8, 24 weeks via the SC route
Study: NCT03459443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan was to be administered as an oral tablet.